Guillem Massana
Research Subjects
Guillem Massana has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Cristóbal Gastó
8 shared publications- Carme Junqué
Medical Psychology Unit, Department of Medicine, Institute of Neurosciences, University of Barcelona, Barcelona, Spain
6 shared publications Rosa Catalán
Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Barcelona Clinic Schizophrenia Unit (BCSU), Institut Clínic de Neurociències (ICN), Hospital Clinic, Barcelona, Spain
6 shared publications- Miquel Bernardo
Ciber de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain
5 shared publications Joan Massana
4 shared publicationsRafael Penadés
Clinical Institute of Neuroscience, Hospital Clínic
4 shared publications
Latest Publications
- 1 March 2016
- Published by Elsevier in Schizophrenia Research
- Vol. 171 (1-3) , 110-116
Cortical thickness in regions of frontal and temporal lobes is associated with responsiveness to cognitive remediation therapy in schizophrenia
- 1 March 2016
- Published by Elsevier in Schizophrenia Research
- Vol. 171 (1-3) , 110-116
Cortical thickness in regions of frontal and temporal lobes is associated with responsiveness to cognitive remediation therapy in schizophrenia
- 1 May 2015
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 25 (5) , 274-277
Hypothalamic–pituitary–adrenal system, neurotrophic factors and clozapine response
Clozapine is an atypical antipsychotic drug known as being more effective compared with traditional antipsychotics for patients with poor response or resistance to treatment. It has been demonstrated that clozapine modulates hypothalamic–pituitary–adrenal activity and affects central brain-derived neurotrophic factor levels, which could explain part of its therapeutic efficacy. In this study, we investigated the role of genes related to the hypothalamic–pituitary–adrenal axis (FKBP5 and NR3C1) and neurotrophic factors (BDNF and NTRK2) in clinical response to clozapine in 591 schizophrenia patients. We found significant allelic and genotype associations between FKBP5-rs1360780, NTRK2-rs1778929 and NTRK2-rs10465180 polymorphisms and clozapine response. The haplotypes composed of rs1360780-rs3777747-rs17542466-rs2766533 (FKBP5) and rs1619120-rs1778929-rs10465180 (NTRK2) were also nominally significant. Our results suggest that genetic variability in FKBP5 and NTRK2 genes may partially explain clinical response to clozapine. Further studies are needed to clarify the involvement of these genes in clinical response to atypical antipsychotics.
- 1 May 2015
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 25 (5) , 274-277
Hypothalamic–pituitary–adrenal system, neurotrophic factors and clozapine response
Clozapine is an atypical antipsychotic drug known as being more effective compared with traditional antipsychotics for patients with poor response or resistance to treatment. It has been demonstrated that clozapine modulates hypothalamic–pituitary–adrenal activity and affects central brain-derived neurotrophic factor levels, which could explain part of its therapeutic efficacy. In this study, we investigated the role of genes related to the hypothalamic–pituitary–adrenal axis (FKBP5 and NR3C1) and neurotrophic factors (BDNF and NTRK2) in clinical response to clozapine in 591 schizophrenia patients. We found significant allelic and genotype associations between FKBP5-rs1360780, NTRK2-rs1778929 and NTRK2-rs10465180 polymorphisms and clozapine response. The haplotypes composed of rs1360780-rs3777747-rs17542466-rs2766533 (FKBP5) and rs1619120-rs1778929-rs10465180 (NTRK2) were also nominally significant. Our results suggest that genetic variability in FKBP5 and NTRK2 genes may partially explain clinical response to clozapine. Further studies are needed to clarify the involvement of these genes in clinical response to atypical antipsychotics.
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S236-S237
Poster #M129 GENETIC VARIABILITY IN THE FKBP5 AND NTRK2 GENES AND CLINICAL RESPONSE TO CLOZAPINE
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S236-S237
Poster #M129 GENETIC VARIABILITY IN THE FKBP5 AND NTRK2 GENES AND CLINICAL RESPONSE TO CLOZAPINE
- 1 May 2013
- Published by Elsevier in Biological Psychiatry
- Vol. 73 (10) , 1015-1023
Brain Effects of Cognitive Remediation Therapy in Schizophrenia: A Structural and Functional Neuroimaging Study
- 1 May 2013
- Published by Elsevier in Biological Psychiatry
- Vol. 73 (10) , 1015-1023
Brain Effects of Cognitive Remediation Therapy in Schizophrenia: A Structural and Functional Neuroimaging Study
- 1 May 2010
- Published by Elsevier in Psychiatry Research
- Vol. 177 (1-2) , 41-45
Executive function needs to be targeted to improve social functioning with Cognitive Remediation Therapy (CRT) in schizophrenia
- 1 May 2010
- Published by Elsevier in Psychiatry Research
- Vol. 177 (1-2) , 41-45
Executive function needs to be targeted to improve social functioning with Cognitive Remediation Therapy (CRT) in schizophrenia
- 1 January 2010
- Published by S. Karger AG in Psychotherapy and Psychosomatics
- Vol. 79 (2) , 129-130
Is Memory Impairment a Rate Limiter in Cognitive Behavioural Therapy for Chronic Schizophrenia?
- 1 January 2010
- Published by S. Karger AG in Psychotherapy and Psychosomatics
- Vol. 79 (2) , 129-130
Is Memory Impairment a Rate Limiter in Cognitive Behavioural Therapy for Chronic Schizophrenia?
- 1 March 2007
- Published by SAGE Publications in AIDS Patient Care and STDs
- Vol. 21 (3) , 212-222
Improvement of Psychosocial Adjustment to HIV-1 Infection through a Cognitive-Behavioral Oriented Group Psychotherapy Program: A Pilot Study
The present study evaluated the efficacy of a group therapy program in improving psychosocial adjustment to HIV infection, and tried to identify variables predictive of greater improvement. The outcome of 47 completing patients was analyzed, comparing the measures between T1 (1 month before therapy), and T2 (first session), and between T2 and T3 (last session) using the Wilcoxon matched-pairs signed-ranks test for each dimension of the Psychosocial Adjustment to Illness Scale (PAIS). The therapy consisted of 16 weekly 2-hour sessions following a structured time-limited cognitive-behavioral group psychotherapy program. During the intervention (between T2 and T3) a significant improvement was observed in health care orientation, vocational environment, domestic environment, sexual relation, extended family relationships, social environment, and total PAIS. There were no changes during baseline (between T1 and T2) in any of the PAIS subscales, or in the total PAIS score. Sexual route of transmission was independently associated with an improvement in health care orientation (β = 2.525). Time since HIV diagnosis (β = 0.022) and being employed (β = 2.548) were independently associated with an improvement in adjustment to vocational environment. Men who have sex with men showed a poorer improvement in adjusting to family relations after the intervention (β = −2.548). Finally, a lower CD4 count (β = −0.005) and being employed (β = 3.054) were independently associated with an improvement in adjustment to social environment. Our psychotherapy program improved psychosocial functioning in a heterogeneous sample of HIV-1–infected patients referred to a consultation-liaison psychiatry unit.
- 1 March 2007
- Published by SAGE Publications in AIDS Patient Care and STDs
- Vol. 21 (3) , 212-222
Improvement of Psychosocial Adjustment to HIV-1 Infection through a Cognitive-Behavioral Oriented Group Psychotherapy Program: A Pilot Study
The present study evaluated the efficacy of a group therapy program in improving psychosocial adjustment to HIV infection, and tried to identify variables predictive of greater improvement. The outcome of 47 completing patients was analyzed, comparing the measures between T1 (1 month before therapy), and T2 (first session), and between T2 and T3 (last session) using the Wilcoxon matched-pairs signed-ranks test for each dimension of the Psychosocial Adjustment to Illness Scale (PAIS). The therapy consisted of 16 weekly 2-hour sessions following a structured time-limited cognitive-behavioral group psychotherapy program. During the intervention (between T2 and T3) a significant improvement was observed in health care orientation, vocational environment, domestic environment, sexual relation, extended family relationships, social environment, and total PAIS. There were no changes during baseline (between T1 and T2) in any of the PAIS subscales, or in the total PAIS score. Sexual route of transmission was independently associated with an improvement in health care orientation (β = 2.525). Time since HIV diagnosis (β = 0.022) and being employed (β = 2.548) were independently associated with an improvement in adjustment to vocational environment. Men who have sex with men showed a poorer improvement in adjusting to family relations after the intervention (β = −2.548). Finally, a lower CD4 count (β = −0.005) and being employed (β = 3.054) were independently associated with an improvement in adjustment to social environment. Our psychotherapy program improved psychosocial functioning in a heterogeneous sample of HIV-1–infected patients referred to a consultation-liaison psychiatry unit.
- 1 April 2006
- Published by Elsevier in Medicina Clinica
- Vol. 126 (13) , 491-492
Tratamiento electroconvulsivo de mantenimiento en la depresión unipolar psicótica del anciano
- 1 April 2006
- Published by Elsevier in Medicina Clinica
- Vol. 126 (13) , 491-492
Tratamiento electroconvulsivo de mantenimiento en la depresión unipolar psicótica del anciano
- 1 April 2005
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 25 (2) , 111-117
Volume Changes in Gray Matter in First-Episode Neuroleptic-Naive Schizophrenic Patients Treated With Risperidone
Structural neuroimaging techniques have consistently shown that treatment of schizophrenic patients with conventional antipsychotics causes an increase in basal ganglia volume. However, findings in schizophrenic patients treated with the newer atypical antipsychotic drugs are less consistently reported. To explore this issue, the authors used a whole-brain, unbiased, and automated technique for comparing brain structural features across scans in schizophrenic patients before and after a treatment with the atypical antipsychotic risperidone. T1-weighted images from 11 first-episode neuroleptic-naive schizophrenic patients were processed and analyzed for regions of interest (basal ganglia) by using optimized voxel-based morphometry. Scans were repeated after 3 months of continuous treatment with risperidone. Region of interest-based voxel-based morphometry analyses revealed increases in gray matter volume for the right and left caudate nuclei and for the left accumbens after the treatment with risperidone. Hence, in our sample of schizophrenic patients, treatment with risperidone was associated, in contrast to the findings for other atypical antipsychotics, with an increase in basal ganglia volume. Such discrepancy could be related to the pharmacodynamics of risperidone (the atypical antipsychotic showing the higher affinity for D2 receptors) and the rather high mean doses used in our study (ie, 6.05 mg/d).
- 1 April 2005
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 25 (2) , 111-117
Volume Changes in Gray Matter in First-Episode Neuroleptic-Naive Schizophrenic Patients Treated With Risperidone
Structural neuroimaging techniques have consistently shown that treatment of schizophrenic patients with conventional antipsychotics causes an increase in basal ganglia volume. However, findings in schizophrenic patients treated with the newer atypical antipsychotic drugs are less consistently reported. To explore this issue, the authors used a whole-brain, unbiased, and automated technique for comparing brain structural features across scans in schizophrenic patients before and after a treatment with the atypical antipsychotic risperidone. T1-weighted images from 11 first-episode neuroleptic-naive schizophrenic patients were processed and analyzed for regions of interest (basal ganglia) by using optimized voxel-based morphometry. Scans were repeated after 3 months of continuous treatment with risperidone. Region of interest-based voxel-based morphometry analyses revealed increases in gray matter volume for the right and left caudate nuclei and for the left accumbens after the treatment with risperidone. Hence, in our sample of schizophrenic patients, treatment with risperidone was associated, in contrast to the findings for other atypical antipsychotics, with an increase in basal ganglia volume. Such discrepancy could be related to the pharmacodynamics of risperidone (the atypical antipsychotic showing the higher affinity for D2 receptors) and the rather high mean doses used in our study (ie, 6.05 mg/d).